Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

Amyloid

Volumn 14, Issue 4, 2007, Pages 277-282

  Liepnieks, Juris J ^a   Benson, Merrill D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; Cardiomyopathy; Liver transplantation; Transthyretin

Indexed keywords

AMYLOID; AMYLOID PROTEIN; PREALBUMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DISEASE COURSE; FAMILIAL AMYLOIDOSIS; GENE; GENETIC VARIABILITY; HEART; HEART AMYLOIDOSIS; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MORTALITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TRANSTHYRETIN AMYLOIDOSIS; TRANSTHYRETIN GENE;

AMYLOID; AMYLOIDOSIS, FAMILIAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LIVER TRANSPLANTATION; MYOCARDIUM; PREALBUMIN;

EID: 35648964702     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120701614032     Document Type: Article

References (31)

1. Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease, 8th ed, Vol. IV, Chapter 209. New York: McGraw-Hill; 2000. pp 5345-5378.
2. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid J Protein Folding Disord 2003;10:160-184.
3. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997;64:74-80.
4. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O'Grady J, Pepys MB, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropthy: implications for amyloid fibrillogenesis. Transplantation 1998;66:229-233.
5. Olofsson B-O, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002;73:745-751.
6. Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116.
7. 30). Clin Genet 1991;40:242-246.
8. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneurpoathy World Transplant Registry. Transplantation 2004;77:64-71.
9. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843-2845.
10. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest 1968;47:924-933.
11. Liepnieks JJ, Wilson DL, Benson MD. Biochemical characterization of vitreous and cardiac amyloid in Ile84Ser transthyretin amyloidosis. Amyloid 2006;13:170-177.
12. Schagger H, Von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1-100 kDA. Anal Biochem 1987;166:368-379.
13. 15.1 hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Commun 1999;260:313-317.
14. Tanaka K, Yamada T, Ohyagi Y, Asahara H, Horiuchi I, Kira J-I. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 2001;183:79-84.
15. Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Therapy 2004;11:838-846.
16. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33:609-618.
17. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-716.
18. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PMP, Feray C, Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1495-1504.
19. Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 1984;81:694-698.
20. Dwulet FE, Benson MD. Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 1986;78:880-886.
21. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986;78:6-12.
22. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003;28:438-442.
23. Benson MD, Dwulet FE. Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum 1983;26:1493-1498.
24. Skinner M, Connors LH, Rubinow A, Libbey C, Sipe JD, Cohen AS. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives. Am J Med Sci 1985;289:17-21.
25. Westermark P, Pitkanen P, Benson L, Vahlquist A, Olofsson BO, Cornwell GG III. Serum prealbumin and retinol-binding protein in the prealbumin-related senile and familial forms of systemic amyloidosis. Lab Invest 1985;52:314-318.
26. Benson MD, Kluve-Beckerman B, Liepnieks JJ, Murrell JR, Hanes D, Uemichi T. Metabolism of amyloid proteins. In: Bock GR, Goode JA, editors. The Nature and Origin of Amyloid Fibrils, Ciba Foundation Symposium 199, John Wiley & Sons Ltd; Chichester, UK. 1996. pp 104-118.
27. Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of Met30 transthyretin and Met119 transthyretin. Eur J Biochem 1997;249:662-668.
28. Bergström J, Gustavsson Å, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson B-O, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005;206:224-232.
29. Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 1989;83:836-843.
30. Hermansen LF, Bergman T, Jörnvall H, Husby G, Ranløv I, Sletten K. Purification and characterization of amyloid-related transthyretin associated and familial amyloidotic cardiomyopathy. Eur J Biochm 1995;227:772-779.
31. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei Y-I, Koyama J, Kawamorita A, Kanno H, Ikeda S-I. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235-242.